Literature DB >> 21118685

Chronic risperidone normalizes elevated pro-inflammatory cytokine and C-reactive protein production in omega-3 fatty acid deficient rats.

Robert K McNamara1, Ronald Jandacek, Therese Rider, Patrick Tso.   

Abstract

Prior clinical and preclinical studies suggest that omega-3 fatty acids negatively regulate pro-inflammatory signaling cascades, and that the atypical antipsychotic risperidone up-regulates omega-3 fatty acid biosynthesis. In the present study, we investigated the effects of chronic (40days) risperidone treatment (3mg/kg/day) on basal pro-inflammatory cytokine (interleukin-6, IL-6; tumor necrosis factor-alpha, TNFα) and C-reactive protein (CRP) production in control and n-3 fatty acid deficient rats. Relationships with erythrocyte polyunsaturated fatty acid composition were determined. Compared with untreated controls, untreated n-3-deficient rats exhibited significantly greater basal IL-6, TNFα, and CRP production. Following chronic risperidone treatment there were trends for greater IL-6, TNFα, and CRP production in controls, but these did not reach significance. In n-3-deficient rats, chronic risperidone normalized elevated IL-6, TNFα, and CRP levels. Erythrocyte arachidonic acid (20:4n-6) composition was positively correlated, and erythrocyte eicosapentenoic (20:5n-3) and docosahexaenoic acid (22:6n-3) inversely correlated, with plasma IL-6, TNFα, and CRP levels in untreated control and n-3-deficient rats, and these associations were not observed among risperidone-treated rats. The adrenic acid (22:4n-6)/arachidonic acid ratio, an index of elongase-mediated arachidonic acid biosynthesis, was reduced by risperidone in controls and elevated in n-3-deficient rats. These preclinical data demonstrate that chronic risperidone treatment normalizes constitutively elevated pro-inflammatory cytokine and CRP production in n-3 fatty acid deficient rats but not in controls, and that the mechanism is dissociable from n-3 fatty acid biosynthesis. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21118685      PMCID: PMC3014435          DOI: 10.1016/j.ejphar.2010.11.010

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  19 in total

1.  Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.

Authors:  Shahin Akhondzadeh; Maryam Tabatabaee; Homayoun Amini; Seyed Ali Ahmadi Abhari; Seyed Hesamedin Abbasi; Behnaz Behnam
Journal:  Schizophr Res       Date:  2007-01-08       Impact factor: 4.939

2.  The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma.

Authors:  Qian Bian; Takahiro Kato; Akira Monji; Sadayuki Hashioka; Yoshito Mizoguchi; Hideki Horikawa; Shigenobu Kanba
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-07-05       Impact factor: 5.067

Review 3.  Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins.

Authors:  Charles N Serhan
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2005-03       Impact factor: 4.294

4.  Omega-3 fatty acid deficiency increases constitutive pro-inflammatory cytokine production in rats: relationship with central serotonin turnover.

Authors:  Robert K McNamara; Ronald Jandacek; Therese Rider; Patrick Tso; Allyson Cole-Strauss; Jack W Lipton
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2010 Oct-Dec       Impact factor: 4.006

5.  Dietary n-3 PUFA deprivation for 15 weeks upregulates elongase and desaturase expression in rat liver but not brain.

Authors:  Miki Igarashi; Kaizong Ma; Lisa Chang; Jane M Bell; Stanley I Rapoport
Journal:  J Lipid Res       Date:  2007-08-22       Impact factor: 5.922

Review 6.  Cytokines in schizophrenia and the effects of antipsychotic drugs.

Authors:  Lukasz Drzyzga; Ewa Obuchowicz; Agnieszka Marcinowska; Zbigniew S Herman
Journal:  Brain Behav Immun       Date:  2006-04-03       Impact factor: 7.217

7.  Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro.

Authors:  Takahiro Kato; Akira Monji; Sadayuki Hashioka; Shigenobu Kanba
Journal:  Schizophr Res       Date:  2007-03-23       Impact factor: 4.939

8.  Uncoupling of interleukin-6 from its signalling pathway by dietary n-3-polyunsaturated fatty acid deprivation alters sickness behaviour in mice.

Authors:  Rozenn Mingam; Aurélie Moranis; Rose-Marie Bluthé; Véronique De Smedt-Peyrusse; Keith W Kelley; Philippe Guesnet; Monique Lavialle; Robert Dantzer; Sophie Layé
Journal:  Eur J Neurosci       Date:  2008-11       Impact factor: 3.386

9.  Omega-3 fatty acid deficiency augments amphetamine-induced behavioral sensitization in adult mice: prevention by chronic lithium treatment.

Authors:  Robert K McNamara; Juliana Sullivan; Neil M Richtand
Journal:  J Psychiatr Res       Date:  2007-07-12       Impact factor: 4.791

10.  Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo.

Authors:  J P Portanova; Y Zhang; G D Anderson; S D Hauser; J L Masferrer; K Seibert; S A Gregory; P C Isakson
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

View more
  11 in total

1.  Gastrointestinal inflammation and associated immune activation in schizophrenia.

Authors:  Emily G Severance; Armin Alaedini; Shuojia Yang; Meredith Halling; Kristin L Gressitt; Cassie R Stallings; Andrea E Origoni; Crystal Vaughan; Sunil Khushalani; F Markus Leweke; Faith B Dickerson; Robert H Yolken
Journal:  Schizophr Res       Date:  2012-03-24       Impact factor: 4.939

Review 2.  Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?

Authors:  Robert K McNamara; Francis E Lotrich
Journal:  Expert Rev Neurother       Date:  2012-09       Impact factor: 4.618

3.  First-episode bipolar disorder is associated with erythrocyte membrane docosahexaenoic acid deficits: Dissociation from clinical response to lithium or quetiapine.

Authors:  Robert K McNamara; Ronald Jandacek; Patrick Tso; Thomas J Blom; Jeffrey A Welge; Jeffrey R Strawn; Caleb M Adler; Melissa P DelBello; Stephen M Strakowski
Journal:  Psychiatry Res       Date:  2015-10-09       Impact factor: 3.222

4.  Risperidone Ameliorates Prefrontal Cortex Neural Atrophy and Oxidative/Nitrosative Stress in Brain and Peripheral Blood of Rats with Neonatal Ventral Hippocampus Lesion.

Authors:  Hiram Tendilla-Beltrán; Silvia Meneses-Prado; Rubén Antonio Vázquez-Roque; Miguel Tapia-Rodríguez; Andrea Judith Vázquez-Hernández; Heriberto Coatl-Cuaya; David Martín-Hernández; Karina S MacDowell; Linda Garcés-Ramírez; Juan C Leza; Gonzalo Flores
Journal:  J Neurosci       Date:  2019-09-13       Impact factor: 6.167

5.  C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications.

Authors:  B S Fernandes; J Steiner; H-G Bernstein; S Dodd; J A Pasco; O M Dean; P Nardin; C-A Gonçalves; M Berk
Journal:  Mol Psychiatry       Date:  2015-07-14       Impact factor: 15.992

Review 6.  Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling.

Authors:  Emily G Severance; Robert H Yolken; William W Eaton
Journal:  Schizophr Res       Date:  2014-07-15       Impact factor: 4.939

7.  Influence of adjuvant Coenzyme Q10 on inflammatory and oxidative stress biomarkers in patients with bipolar disorders during the depressive episode.

Authors:  Leila Jahangard; Fatemeh Yasrebifar; Mohammad Haghighi; Akram Ranjbar; Maryam Mehrpooya
Journal:  Mol Biol Rep       Date:  2019-07-25       Impact factor: 2.316

Review 8.  From Infection to the Microbiome: An Evolving Role of Microbes in Schizophrenia.

Authors:  Emily G Severance; Robert H Yolken
Journal:  Curr Top Behav Neurosci       Date:  2020

9.  A 16-week randomized placebo-controlled trial investigating the effects of omega-3 polyunsaturated fatty acid treatment on white matter microstructure in recent-onset psychosis patients concurrently treated with risperidone.

Authors:  Amanda E Lyall; Felix L Nägele; Ofer Pasternak; Juan A Gallego; Anil K Malhotra; Robert K McNamara; Marek Kubicki; Bart D Peters; Delbert G Robinson; Philip R Szeszko
Journal:  Psychiatry Res Neuroimaging       Date:  2020-11-04       Impact factor: 2.376

Review 10.  Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.

Authors:  Willem Johan van den Brink; Semra Palic; Isabelle Köhler; Elizabeth Cunera Maria de Lange
Journal:  Pharm Res       Date:  2018-02-15       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.